11 Apr '17, 1pm

For a brief description, plus to request more information, please follow this link:

Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD) . (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin GVHD is permitted.) Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to their first day of study drug administration. (Hydroxyurea is allowed prior to enrollment and after the start of AG-120). Subjects who received an investigational agent <14 days prior to their first day of study drug administration. Subjects who previously received prior treatment with a mutant-specific IDH1 inhibitor and progressed on therapy Subjects who are pregnant or breastfeeding. Subjects with an active severe infection or with ...

Full article: http://www.aamds.org/treatments/clinical-trials/phase-1-m...

Tweets

SearchCap: Advanced analytics, fake listings on...

searchengineland.com 11 Apr '17, 8pm

5 hot trends in advanced analytics Apr 11, 2017 by Digital Marketing Depot Marketing data is everywhere. With so many new ...